Introduction: We wanted to elucidate whether the proposed advantages of citalopram-buspirone combination
treatment are related to changes in 5-HT2A/C receptor-mediated neurotransmission. Methods: The affinity of buspirone to 5-HT2A and 5-HT2C receptors was measured in vitro, and the influence of buspirone on 5-HT2C receptor-mediated phosphoinositide hydrolysis was estimated. Four groups of rats
received citalopram (10 mg/kg), buspirone (6 mg/kg), citalopram-buspirone combination,
or saline once a day s. c. for 14 days. Treatment effects on 5-HT2A and 5-HT2C receptors were investigated by receptor autoradiography with antagonist and agonist
radioligands. Results: Buspirone was found to be a weak 5-HT2C receptor antagonist, with a low affinity for 5-HT2A and 5-HT2C receptors. Repeated buspirone-citalopram combination treatment markedly decreased
[3H]ketanserin and [125I]DOI binding to 5-HT2A receptors. Repeated administration of buspirone and buspirone-citalopram combination
increased the affinity of [3H]mesulergine toward 5-HT2C receptors, and buspirone-citalopram combination also decreased [125I]DOI binding to 5-HT2C receptors. Discussion: We suggest that downregulation of brain 5-HT2A receptors and possibly of 5-HT2C receptor agonist sites is involved in the beneficial clinical effects of buspirone-SSRI
augmentation treatment. Furthermore, a conversion of brain 5-HT2C receptors from high- to low-affinity state may provide an additional mechanism for
the anti-anxiety effects of buspirone.
Abbreviations
Bmax:maximum receptor density
DOI:(+-)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane
5-HT:serotonin (5-hydroxytryptamine)
IP:inositol monophosphate
K
d:equilibrium dissociation constant (affinity)
K
i:inhibition constant
KRB:Krebs-bicarbonate
PI:phosphoinositide
1-PP:1-(2-pyrimidinyl)piperazine
SSRI:selective serotonin reuptake inhibitor
References
- 1
Appel N M, Mitchell W M, Garlick R K, Glennon R A, Teitler M, De Souza E B.
Autoradiographic characterization of (+-)-1-(2,5-dimethoxy-4-[125I] iodophenyl)-2-aminopropane
([125I]DOI) binding to 5-HT2 and 5-HT1c receptors in rat brain.
J Pharmacol Exp Ther.
1990;
255
843-857
- 2
Appelberg B G, Syvälahti E K, Koskinen T E, Mehtonen O P, Muhonen T T, Naukkarinen H H.
Patients with severe depression may benefit from buspirone augmentation of selective
serotonin reuptake inhibitors: results from a placebo-controlled, randomized, double-blind,
placebo wash-in study.
J Clin Psychiatry.
2001;
62
448-452
- 3
Ashby C RJ, Edwards E, Wang R Y.
Electrophysiological evidence for a functional interaction between 5-HT1A and 5-HT2A
receptors in the rat medial prefrontal cortex: an iontophoretic study.
Synapse.
1994;
17
173-181
- 4
Aznar S, Qian Z, Shah R, Rahbek B, Knudsen G M.
The 5-HT1A serotonin receptor is located on calbindin- and parvalbumin-containing
neurons in the rat brain.
Brain Res.
2003;
959
58-67
- 5
Baldwin D, Rudge S.
The role of serotonin in depression and anxiety.
Int Clin Psychopharmacol.
1995;
9
41-45
- 6
Barker E L, Westphal R S, Schmidt D, Sanders-Bush E.
Constitutively active 5-hydroxytryptamine2C receptors reveal novel inverse agonist
activity of receptor ligands.
J Biol Chem.
1994;
269
11 687-11 690
- 7
Blier P, Ward N M.
Is there a role for 5-HT1A agonists in the treatment of depression?.
Biol Psychiatry.
2003;
53
193-203
- 8
Bouwer C, Stein D J.
Buspirone is an effective augmenting agent of serotonin selective reuptake inhibitors
in severe treatment-refractory depression.
S Afr Med J.
1997;
87
534-537, 540
- 9
Dhaenen H.
Imaging the serotonergic system in depression.
Eur Arch Psychiatry Clin Neurosci.
2001;
251
1176-1180
- 10
Dimitriou E C, Dimitriou C E.
Buspirone augmentation of antidepressant therapy.
J Clin Psychopharmacol.
1998;
18
465-469
- 11
Dolberg O T, Klag E, Gross Y, Schreiber S.
Relief of serotonin selective reuptake inhibitor induced sexual dysfunction with low-dose
mianserin in patients with traumatic brain injury.
Psychopharmacology (Berl).
2002;
161
404-407
- 12
Egan C, Grinde E, Dupre A, Roth B L, Hake M, Teitler M, Herrick-Davis K.
Agonist high and low affinity state ratios predict drug intrinsic activity and a revised
ternary complex mechanism at serotonin 5-HT(2A) and 5-HT(2C) receptors.
Synapse.
2000;
35
144-150
- 13
Fava M.
Augmentation and combination strategies in treatment-resistant depression.
J Clin Psychiatry.
2001;
62
4-11
- 14
Frank E, Karp J F, Rush A J.
Efficacy of treatments for major depression.
Psychopharmacol Bull.
1993;
29
457-475
- 15
Gibson E L, Barnfield A M, Curzon G.
Evidence that mCPP-induced anxiety in the plus-maze is mediated by postsynaptic 5-HT2C
receptors but not by sympathomimetic effects.
Neuropharmacology.
1994;
33
457-465
- 16
Gobert A, Rivet J M, Cistarelli L, Melon C, Millan M J.
Alpha2-adrenergic receptor blockade markedly potentiates duloxetine- and fluoxetine-induced
increases in noradrenaline, dopamine, and serotonin levels in the frontal cortex of
freely moving rats.
J Neurochem.
1997;
69
2616-2619
- 17
Gobert A, Rivet J M, Cistarelli L, Melon C, Millan M J.
Buspirone modulates basal and fluoxetine-stimulated dialysate levels of dopamine,
noradrenaline and serotonin in the frontal cortex of freely moving rats: activation
of serotonin1A receptors and blockade of alpha2-adrenergic receptors underlie its
actions.
Neuroscience.
1999;
93
1251-1262
- 18
Golembiowska K, Dziubina A.
Effect of acute and chronic administration of citalopram on glutamate and aspartate
release in the rat prefrontal cortex.
Pol J Pharmacol.
2000;
52
441-448
- 19
Graeff F G, Guimaraes F S, De Andrade T G, Deakin J F.
Role of 5-HT in stress, anxiety, and depression.
Pharmacol Biochem Behav.
1996;
54
129-141
- 20
Gray J A, Roth B L.
Paradoxical trafficking and regulation of 5-HT(2A) receptors by agonists and antagonists.
Brain Res Bull.
2001;
56
441-451
- 21
Haddjeri N, Blier P, de Montigny C.
Long-term antidepressant treatments result in a tonic activation of forebrain 5-HT1A
receptors.
J Neurosci.
1998;
18
10 150-10 156
- 22
Harvey K V, Balon R.
Augmentation with buspirone: a review.
Ann Clin Psychiatry.
1997;
7
143-147
- 23
Hietala J, Salonen I, Lappalainen J, Syvälahti E.
Ethanol administration does not alter dopamine D1 and D2 receptor characteristics
in rat brain.
Neurosci Lett.
1990;
108
289-294
- 24
Hjorth S, Auerbach S B.
Lack of 5-HT1A autoreceptor desensitization following chronic citalopram treatment,
as determined by in vivo microdialysis.
Neuropharmacology.
1994;
33
331-334
- 25
Hoyer D, Clarke D E, Fozard J R, Hartig P R, Martin G R, Mylecharane E J, Saxena P R,
Humphrey P P.
VII. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine
(Serotonin).
Pharmacol Rev.
1994;
46
157-203
- 26
Jenck F, Moreau J L, Mutel V, Martin J R, Haefely W E.
Evidence for a role of 5-HT1C receptors in the antiserotonergic properties of some
antidepressant drugs.
Eur J Pharmacol.
1993;
231
223-229
- 27
Joffe R T, Schuller D R.
An open study of buspirone augmentation of serotonin reuptake inhibitors in refractory
depression.
J Clin Psychiatry.
1993;
54
269-271
- 28
Julius D, MacDermott A B, Axel R, Jessell T M.
Molecular characterization of a functional cDNA encoding the serotonin 1c receptor.
Science.
1988;
241
558-564
- 29
Kennett G A.
5-HT1C receptor antagonists have anxiolytic-like actions in the rat social interaction
model.
Psychopharmacology (Berl).
1992;
107
379-384
- 30
Klimek V, Zak-Knapik J, Mackowiak M.
Effects of repeated treatment with fluoxetine and citalopram, 5-HT uptake inhibitors,
on 5-HT1A and 5-HT2 receptors in the rat brain.
J Psychiatry Neurosci.
1994;
19
63-67
- 31
Kuoppamäki M, Pälvimäki E P, Syvälahti E, Hietala J.
5-HT1C receptor-mediated phosphoinositide hydrolysis in the rat choroid plexus after
chronic treatment with clozapine.
Eur J Pharmacol.
1994;
255
91-97
- 32
Kuoppamäki M, Seppälä T, Syvälahti E, Hietala J.
Regulation of serotonin 5-HT2C receptors in the rat choroid plexus after acute clozapine
treatment.
Eur J Pharmacol.
1994;
269
201-208
- 33
Kuoppamäki M, Syvälahti E, Hietala J.
Clozapine and N-desmethylclozapine are potent 5-HT1C receptor antagonists.
Eur J Pharmacol.
1993;
245
179-182
- 34
Laakso A, Pälvimäki E P, Kuoppamäki M, Syvälahti E, Hietala J.
Chronic citalopram and fluoxetine treatments upregulate 5-HT2c receptors in the rat
choroid plexus.
Neuropsychopharmacology.
1996;
15
143-151
- 35
Lafaille F, Welner S A, Suranyi-Cadotte B E.
Regulation of serotonin type 2 (5-HT2) and beta-adrenergic receptors in rat cerebral
cortex following novel and classical antidepressant treatment.
J Psychiatry Neurosci.
1991;
16
209-214
- 36
Landen M, Bjorling G, Agren H, Fahlen T.
A randomized, double-blind, placebo-controlled trial of buspirone in combination with
an SSRI in patients with treatment-refractory depression.
J Clin Psychiatry.
1998;
59
664-668
- 37
Landen M, Eriksson E, Agren H, Fahlen T.
Effect of buspirone on sexual dysfunction in depressed patients treated with selective
serotonin reuptake inhibitors.
J Clin Psychopharmacol.
1999;
19
268-271
- 38
Lucaites V L, Nelson D L, Wainscott D B, Baez M.
Receptor subtype and density determine the coupling repertoire of the 5-HT2 receptor
subfamily.
Life Sci.
1996;
59
1081-1095
- 39
Maj J, Moryl E.
Effects of sertraline and citalopram given repeatedly on the responsiveness of 5-HT
receptor subpopulations.
J Neural Transm Gen Sect.
1992;
88
143-156
- 40
Marek G J, Carpenter L L, McDougle C J, Price L H.
Synergistic action of 5-HT2A antagonists and selective serotonin reuptake inhibitors
in neuropsychiatric disorders.
Neuropsychopharmacology.
2003;
28
402-412
- 41
Miner L A, Backstrom J R, Sanders-Bush E, Sesack S R.
Ultrastructural localization of serotonin2A receptors in the middle layers of the
rat prelimbic prefrontal cortex.
Neuroscience.
2003;
116
107-117
- 42
Nocjar C, Roth B L, Pehek E A.
Localization of 5-HT(2A) receptors on dopamine cells in subnuclei of the midbrain
A10 cell group.
Neuroscience.
2002;
111
163-176
- 43
Okazawa H, Yamane F, Blier P, Diksic M.
Effects of acute and chronic administration of the serotonin1A agonist buspirone on
serotonin synthesis in the rat brain.
J Neurochem.
1999;
72
2022-2031
- 44
Onder E, Tural U.
Faster response in depressive patients treated with fluoxetine alone than in combination
with buspirone.
J Affect Disord.
2003;
76
223-227
- 45 Paxinos G, Watson C. The rat brain in stereotaxic coordinates (4th edition). San
Diego, USA; Academic Press 1998
- 46
Pazos A, Cortes R, Palacios J M.
Quantitative autoradiographic mapping of serotonin receptors in the rat brain. II.
Serotonin-2 receptors.
Brain Res.
1985;
346
231-249
- 47
Peroutka S J, Howell T A.
The molecular evolution of G protein-coupled receptors: focus on 5-hydroxytryptamine
receptors.
Neuropharmacology.
1994;
33
319-324
- 48
Petty F, Davis L L, Kabel D, Kramer G L.
Serotonin dysfunction disorders: a behavioral neurochemistry perspective.
J Clin Psychiatry.
1996;
57 Suppl 8
11-16
- 49
Pranzatelli M R.
Regulation of 5-HT2 receptors in rat cortex. Studies with a putative selective agonist
and an antagonist.
Biochem Pharmacol.
1991;
42
1099-1105
- 50
Pälvimäki E P, Roth B L, Majasuo H, Laakso A, Kuoppamäki M, Syvälahti E, Hietala J.
Interactions of selective serotonin reuptake inhibitors with the serotonin 5-HT2c
receptor.
Psychopharmacology (Berl).
1996;
126
234-240
- 51
Rickels K.
Buspirone in clinical practice.
J Clin Psychiatry.
1990;
51
51-54
- 52
Roth B L, Hamblin M, Ciaranello R D.
Regulation of 5-HT2 and 5-HT1C serotonin receptor levels. Methodology and mechanisms.
Neuropsychopharmacology.
1990;
3
427-433
- 53
Rowan M J, Anwyl R.
Neurophysiological effects of buspirone and isapirone in the hippocampus: comparison
with 5-hydroxytryptamine.
Eur J Pharmacol.
1986;
132
93-96
- 54
Sanders-Bush E, Breeding M.
Serotonin1c receptor reserve in choroid plexus masks receptor subsensitivity.
J Pharmacol Exp Ther.
1990;
252
984-988
- 55
Saxena P R.
Serotonin receptors: subtypes, functional responses and therapeutic relevance.
Pharmacol Ther.
1995;
66
339-368
- 56 Seeman P. Receptor Tables, vol. 2: Drug dissociation constants for neuroreceptors
and transporters. Toronto, Canada; SZ Research 1993
- 57
Skrebuhhova T, Allikmets L, Matto V.
[3H]-ketanserin binding and elevated plus-maze behavior after chronic antidepressant
treatment in DSP-4 and P-CPA pretreated rats: evidence for partial involvement of
5-HT2A receptors.
Methods Find Exp Clin Pharmacol.
1999;
21
483-490
- 58
Stadel J M, De Lean A, Lefkowitz R J.
Molecular mechanisms of coupling in hormone reseptor - adenylate cyclase systems.
Adv Enzymol Relat Areas Mol Biol.
1982;
53
1-43
- 59
Van Oekelen D, Luyten W H, Leysen J E.
5-HT2A and 5-HT2C receptors and their atypical regulation properties.
Life Sci.
2003;
72
2429-2449
- 60
VanderMaelen C P, Matheson G K, Wilderman R C, Patterson L A.
Inhibition of serotonergic dorsal raphe neurons by systemic and iontophoretic administration
of buspirone, a non-benzodiazepine anxiolytic drug.
Eur J Pharmacol.
1986;
129
123-130
- 61
Willins D L, Deutch A Y, Roth B L.
Serotonin 5-HT2A receptors are expressed on pyramidal cells and interneurons in the
rat cortex.
Synapse.
1997;
27
79-82
Prof. Erkka Syvälahti
Department of Pharmacology and Clinical Pharmacology
University of Turku
Itäinen Pitkäkatu 4 B
20520 Turku
FINLAND
Phone: +358 2 333 7582
Fax: +358 2 333 7216
Email: erkka.syvalahti@utu.fi